BMJ Case Reports

Upadacitinib salvage for refractory immune checkpoint inhibitor colitis complicated by cytomegalovirus infection

Immune checkpoint inhibitor colitis is a common immune-related adverse event associated with immunotherapy and may be refractory to corticosteroids and biologic therapy. Evidence guiding management ...
Healio

Early biologic use may cut rehospitalization risk in immune checkpoint inhibitor colitis

Please provide your email address to receive an email when new articles are posted on . High-dose steroid use independently predicted hospital readmission for patients with immune checkpoint inhibitor ...
MobiHealthNews

EMR-based algorithm identifies patients at risk of serious cancer therapy side effects

Researchers at Peter MacCallum Cancer Centre have developed a digital phenotype to assist with automatically identifying ...
ascopubs.org

Risk of Colitis in Patients With Inflammatory Bowel Disease or Microscopic Colitis Exposed to Checkpoint Inhibitors: A National Danish Cohort Study

Changes in Medicaid Enrollment Among Adult Survivors of Childhood Cancer After Medicaid Expansion: A Report From the Childhood Cancer Survivor Study Patients with intestinal inflammatory diseases such ...
Medscape

GI Side Effects of Immune Checkpoint Inhibitors Linked to Colon Adenoma Risk

PHOENIX — Patients treated for cancer with immune checkpoint inhibitors (ICIs) who develop the drugs’ known side effects of diarrhea and colitis experience increased risk of adenomas in the colon — ...
The Manila Times

Seres Therapeutics to Host Webcast on July 8, 2026, to Discuss Results of Investigator-Sponsored Trial of Seres’ SER-155 in Immune Checkpoint Inhibitor-Related Enterocolitis

Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that it will host a webcast to discuss top-line results from an investigator-sponsored trial (IST) ...